Avalo Therapeutics Stock Price, News & Analysis
AVTX
NASDAQ
Company Description
Welcome to the overview page for Avalo Therapeutics (AVTX), where you can find comprehensive stock information and company updates.
Explore the latest news on strategic partnerships, quarterly and annual financial results, and regulatory filings including SEC reports and insider transactions.
Visualize performance trends using the interactive price chart, and keep track of upcoming events such as earnings calls, dividend dates, and investor conferences.
Stock Performance
$18.37
0.00%
0.00
Last updated: December 29, 2025 at 07:38
102.09 %
Performance 1 year
$342.9M
18.1M
Latest News
SEC Filings
Insider Radar
Net Sellers
90-Day Summary
0
Shares Bought
11,367
Shares Sold
2
Transactions
Most Recent Transaction
Goldman Jonathan
(Director)
sold
3,167 shares
@ $14.30
on Nov 14, 2025
Based on SEC Form 4 filings over the last 90 days.
Financial Highlights
$441,000
Revenue (TTM)
-$35,129,000
Net Income (TTM)
-$20.91
-$49,056,000
Operating Cash Flow
-7,965.76%
-15,535.60%
Upcoming Events
JAN
01
January 1, 2026
Clinical
Phase 2 LOTUS topline data
JAN
01
January 1, 2026
Clinical
Phase 2 LOTUS trial readout
JAN
01
January 1, 2026
Clinical
Phase 2 LOTUS topline data
MAY
01
May 1, 2026 - August 31, 2026
Clinical
Phase 2 trial results
AVTX-009 Phase 2 hidradenitis suppurativa trial readout expected
MAY
01
May 1, 2026 - August 31, 2026
Clinical
LOTUS Phase 2 data readout
Data readout window for AVTX-009 LOTUS Phase 2 trial
MAY
01
May 1, 2026 - August 31, 2026
Clinical
Topline data readout
Readout of Phase 2 LOTUS trial topline data
MAY
01
May 1, 2026 - August 31, 2026
Clinical
Phase 2 LOTUS topline data
Expected topline data release for Phase 2 LOTUS trial in hidradenitis suppurativa
MAY
01
May 1, 2026 - August 31, 2026
Clinical
LOTUS topline data release
Topline data from Phase 2 LOTUS trial expected mid-2026
MAY
01
May 1, 2026 - August 31, 2026
Clinical
LOTUS trial topline data
Topline data expected mid-2026 for Phase 2 LOTUS hidradenitis suppurativa trial
Short Interest History
Last 12 Months
Loading short interest data...
Days to Cover History
Last 12 Months
Loading days to cover data...
Frequently Asked Questions
What is the current stock price of Avalo Therapeutics (AVTX)?
The current stock price of Avalo Therapeutics (AVTX) is $18.37 as of December 26, 2025.
What is the market cap of Avalo Therapeutics (AVTX)?
The market cap of Avalo Therapeutics (AVTX) is approximately 342.9M. Learn more about what market capitalization means .
What is the revenue (TTM) of Avalo Therapeutics (AVTX) stock?
The trailing twelve months (TTM) revenue of Avalo Therapeutics (AVTX) is $441,000.
What is the net income of Avalo Therapeutics (AVTX)?
The trailing twelve months (TTM) net income of Avalo Therapeutics (AVTX) is -$35,129,000.
What is the earnings per share (EPS) of Avalo Therapeutics (AVTX)?
The diluted earnings per share (EPS) of Avalo Therapeutics (AVTX) is -$20.91 on a trailing twelve months (TTM) basis. Learn more about EPS .
What is the operating cash flow of Avalo Therapeutics (AVTX)?
The operating cash flow of Avalo Therapeutics (AVTX) is -$49,056,000. Learn about cash flow.
What is the profit margin of Avalo Therapeutics (AVTX)?
The net profit margin of Avalo Therapeutics (AVTX) is -7,965.76%. Learn about profit margins.
What is the operating margin of Avalo Therapeutics (AVTX)?
The operating profit margin of Avalo Therapeutics (AVTX) is -15,535.60%. Learn about operating margins.
What is the current ratio of Avalo Therapeutics (AVTX)?
The current ratio of Avalo Therapeutics (AVTX) is 19.96, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.
What is the operating income of Avalo Therapeutics (AVTX)?
The operating income of Avalo Therapeutics (AVTX) is -$68,512,000. Learn about operating income.